普蕊斯（上海）医药科技开发股份有限公司 独立董事关于 2023 年半年度相关事项 二、关于公司控股股东及其他关联方资金占用及对外担保情况的专项说明 和独立意见 根据中国证监会《上市公司监管指引第 8 号——上市公司资金往来、对外担 保的监管要求》《上市公司独立董事规则》及《公司章程》的有关规定，作为公 司独立董事，对公司报告期内对外担保情况以及控股股东及其他关联方占用资金 的情况进行了认真的调查和核查，发表专项说明及独立意见如下： 1、报告期内，公司认真贯彻《上市公司监管指引第 8 号——上市公司资金 往来、对外担保的监管要求》《公司章程》等有关规定，严格控制控股股东及其 他关联方资金占用风险。截至本报告期末，公司不存在控股股东及其他关联方占 用上市公司资金的情况，也不存在以前年度发生累计至本报告期末的违规关联方 资金占用情况。 及公司第三届董事会第三次会议相关事项的独立意见 2、经核查，报告期内，公司及全资子公司不存在对外担保的情况，不存在 为控股股东、实际控制人及其他关联方提供对外担保的情形，不存在通过对外担 保损害公司利益及其他股东利益的情形，也不存在以前年度累计至 2023 年 6 月 30 日违规对 ...

证券代码：301257 证券简称：普蕊斯 普蕊斯（上海）医药科技开发股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------------|-----------------------|-----------| | | | | | | □媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 | □路演活动 | | | □现场参观 □券商策略会 | | | | □其他 | | | 参与单位名称及人员姓名 | 奥博资本、海通证券共 | 6 人 | 时间 2023 年 7 月 24 日 地点 上海公司会议室 上市公司接待 人员姓名 董事会秘书 赖小龙 一、介绍公司基本情况 普蕊斯作为国内领先的大数据驱动型创新 SMO，为国内外 制药公司等客户提供包括前期准备计划、试验点启动、现场执 行、项目全流程管理等服务，实现临床试验现场管理外包的一站 式服务，从而更加高效快速地推进申办方临床试验的落地和执 投资者关系 行。 公司自创立初期便致力于承接具有创新性及高临床价值新药 活动主要 的 SMO 项目，SMO 执行项目数量亦稳步增长，截至 2023 ...

证券代码：301257 证券简称：普蕊斯 普蕊斯（上海）医药科技开发股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------|-------------------------|------------| | | | | | | □媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 | □路演活动 | | | □现场参观 | 券商策略会 | | | 其他 （投资者线上会议） | | 招商基金、兴证全球基金、华安基金、景顺长城基金、中银基 参与单位名称 金、兴业基金、永赢基金、安信基金、开源基金、摩根士丹利华 及人员姓名 鑫基金、中金资管、玖鹏资管、国君资管、国华兴益保险、开源 证券、太平洋证券、华西证券等共 25 家机构 36 人 时间 2023 年 7 月 3 日—7 月 4 日、2023 年 7 月 11 日 地点 上海公司会议室 上海香格里拉大酒店 上市公司接待 人员姓名 董事会秘书 赖小龙 一、介绍公司基本情况 普蕊斯作为国内领先的大数据驱动型创新 SMO，为国内外 制药公司等客户提供包括前期准备计划、试验点启动、现场 ...

Company Overview - Prasis is a leading data-driven innovative SMO in China, providing comprehensive services for clinical trial management, including preparation, site initiation, and full project management [2][3]. - As of March 31, 2023, the company has participated in over 2,500 SMO projects, with 1,505 currently active [3][4]. - The company employs over 3,700 professionals and serves nearly 800 clinical trial institutions across more than 160 cities in China [3][5]. Market Position and Growth - Prasis collaborates with top global pharmaceutical companies and CROs, establishing a strong presence in 24 therapeutic areas, including oncology and infectious diseases [3][4]. - The demand for clinical trials in China is expected to grow due to increasing pharmaceutical R&D spending and a shift towards innovative drug development [4][6]. - The company has successfully launched over 110 products domestically and internationally [5]. Competitive Advantages - Prasis is among the top-tier SMO companies in China, leveraging its early entry into the market and specialized service capabilities [4][5]. - The company has established a comprehensive SOP system and a robust training framework, ensuring high-quality and reliable clinical trial execution [5][6]. - Management possesses over 10 years of industry experience, enhancing the company's operational stability and project management capabilities [5][6]. Regulatory Environment and Future Outlook - The regulatory landscape in China is increasingly supportive of R&D innovation, emphasizing patient-centered approaches and high-quality clinical trials [4][6]. - The company anticipates a continued rise in the demand for SMO services as regulatory requirements for clinical trial data quality become more stringent [4][6]. - Long-term growth in the innovative drug market is expected due to factors such as economic growth, aging population, and increasing healthcare demands [4][6].

证券代码：301257 证券简称：普蕊斯 普蕊斯（上海）医药科技开发股份有限公司 投资者关系活动记录表 | --- | --- | --- | |---------------------|-------------------------|--------------------------| | | | 特定对象调研 □分析师会议 | | | □媒体采访 □业绩说明会 | | | 投资者关系 活动类别 | □新闻发布会 □路演活动 | | | | □现场参观 □券商策略会 | | | | 其他 （投资者线上会议） | | 鹏华基金、摩根士丹利基金、平安养老保险、光大证券、长江证 参与单位名称 及人员姓名 券、长城国瑞证券共 6 家机构 10 人 时间 2023 年 6 月 2 日、6 月 6 日-6 月 7 日 地点 上海公司会议室 上市公司接待 人员姓名 董事会秘书 赖小龙 一、介绍公司基本情况 普蕊斯作为国内领先的大数据驱动型创新 SMO，为国内外 制药公司等客户提供包括前期准备计划、试验点启动、现场执 行、项目全流程管理等服务，实现临床试验现场管理外包的一站 式服务，从而更加高效快速地推进申办方临床 ...

Group 1: Company Overview - Proris (Shanghai) Pharmaceutical Technology Development Co., Ltd. is a leading data-driven innovation company in China, providing comprehensive services for clinical trial management [2][3]. - As of March 31, 2023, the company has participated in over 2,500 SMO projects, with 1,505 projects currently in execution [3][4]. - The company employs over 3,700 professionals and serves nearly 800 clinical trial institutions, covering more than 1,300 clinical trial sites across over 160 cities in China [3][4]. Group 2: Clientele and Market Position - The primary clients include international pharmaceutical companies and well-known domestic innovative pharmaceutical companies, collaborating with the top 10 global pharmaceutical companies and CROs [3][4]. - The company has established a strong brand and reputation in the industry, participating in 24 therapeutic areas, including oncology, endocrine diseases, and infectious diseases [3][4]. Group 3: Competitive Advantages - Proris is among the first entrants in the SMO industry, recognized as a qualified supplier for major pharmaceutical companies such as Merck, Novartis, and AbbVie [4][5]. - The company has a comprehensive standard operating procedure (SOP) for clinical trials, ensuring high-quality and efficient execution of clinical trial projects [4][5]. - The company maintains a stable client relationship due to its strict quality control and efficient talent replication systems, reducing the risk of client attrition [5][6]. Group 4: Financial Performance - In 2022, the company achieved a new contract amount of 1,042.85 million yuan, representing a year-on-year growth of 43.42% [5][6]. - The increase in orders is attributed to the continuous investment in R&D by global pharmaceutical companies and the rising demand for SMO services for new drug clinical trials [5][6]. Group 5: Future Plans - In 2023, the company aims to enhance resource allocation and inter-departmental empowerment through information technology upgrades, striving for a leading position in the industry [5][6]. - The focus will be on optimizing management processes and improving operational efficiency to achieve the set goals for the year [5][6].

证券代码：301257 证券简称：普蕊斯 普蕊斯（上海）医药科技开发股份有限公司 投资者关系活动记录表 | --- | --- | |---------------------|-----------------------| | | | | | □媒体采访 □业绩说明会 | | 投资者关系 活动类别 | □新闻发布会 □路演活动 | | | □现场参观 券商策略会 | □其他 （请文字说明其他活动内容） 易方达、华夏基金、景顺长城、华宝基金、汇安基金、大成 基金、海富通基金、华夏未来资本、西部利得基金、中海基 金、摩根华鑫、光大保德信资管、华夏久盈资管、德邦资 参与单位名 管、平安资管、招银理财、中邮保险、建信养老金、上海仙 称及人员姓 人掌私莫基金、长鸿资本、睿华资本、爱乐辰峰资本、肇万 名 资产、永望资产、趣时资产、相聚资本、彝川资本、源乘投 资、汇升投资、国鸣投资、欣歌投资、森锦投资、洋谊投资 等 47 家机构家机构 53 人 时间 2023 年 5 月 8 日-5 月 12 日 上海柏悦酒店 上海金茂君悦大酒店 上海裕景大饭店 上海香格里拉大酒店 上海东方滨江大酒店 上海会议室 地点 电话会议 上市 ...

证券代码：301257 证券简称：普蕊斯 普蕊斯（上海）医药科技开发股份有限公司 投资者关系活动记录表 编号：2023-006 投资者关系 活动类别 □特定对象调研 □分析师会议 □媒体采访 业绩说明会 □新闻发布会 □路演活动 □现场参观 □券商策略会 □其他 （请文字说明其他活动内容） 参与单位名称 及人员姓名 线上参与公司 2022 年度报告业绩说明会的投资者 时间 2023 年 5 月 9 日(周二)15:00～17:00 地点 上海证券报·中国证券网路演中心： https://roadshow.cnstock.com/ 上市公司接待 人员姓名 董事长赖春宝 总经理杨宏伟 董事会秘书赖小龙 财务总监宋卫红 独立董事廖县生 保荐代表人徐妍薇 投资者关系 活动主要 内容介绍 本次业绩说明会问答环节主要内容如下： 1、SMO 行业进入壁垒高吗？ 尊敬的投资者您好，SMO 行业壁垒情况如下： ①客户准入壁垒： 临床试验的申办方对 SMO 供应商制定了一套严格的考核流 程，申办方尤其是外企或者大型药企的 QA 团队，通常会对 SMO 供应商展开约 3-9 个月的系统稽查流程，只有通过系统稽查后 才能被纳入合格供 ...

证券代码：301257 证券简称：普蕊斯 普蕊斯（上海）医药科技开发股份有限公司 投资者关系活动记录表 编号：2023-005 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系 □新闻发布会 □路演活动 活动类别 □现场参观 券商策略会 其他 （由长江证券、兴业证券、中信建投证券、东吴证券、 申万宏源证券、东北证券、华西证券和国元证券联合组织的 2022 年度暨 2023 年第一季度电话交流会） 易方达基金、天弘基金、南方基金、博时基金、富国基金、汇 添富基金、中欧基金、工银安盛、兴证全球基金、华安基金、 交银施罗德基金、景顺长城基金、兴业基金、永赢基金、前海 开源基金、光大保德信、泓德基金、宝盈基金、东兴基金、东 方红、海通证券资管、中国人寿资管、光证资管、德邦证券资 参与单位名称 管、中信建投资管、华夏未来资管、景林资管、英大保险资 及人员姓名 管、野村资管、中金公司、国任保险、建信养老、永诚财险、 英大国际信托、东方自营、中银国际自营、高毅资产、淡水泉 投 资 、拾 贝 投资 、 Keywise Capital 、 Orbimed Capital 、 Point72 等共 121 家机构 ...

Financial Performance - The company's operating revenue for 2022 was ¥586,231,829.02, representing a 16.55% increase compared to ¥502,966,742.06 in 2021[19]. - The net profit attributable to shareholders for 2022 was ¥72,411,406.83, a 25.35% increase from ¥57,769,029.71 in 2021[19]. - The net profit after deducting non-recurring gains and losses was ¥66,919,992.34, up 16.18% from ¥57,600,837.16 in 2021[19]. - The total assets at the end of 2022 reached ¥1,160,719,180.61, a significant increase of 187.13% from ¥404,248,815.63 at the end of 2021[19]. - The net assets attributable to shareholders increased by 315.99% to ¥951,967,793.10 at the end of 2022 from ¥228,843,138.26 at the end of 2021[19]. - The company reported a basic earnings per share of ¥1.35 for 2022, reflecting a 5.47% increase from ¥1.28 in 2021[19]. - The weighted average return on equity decreased to 11.39% in 2022 from 29.00% in 2021, a decline of 17.61%[19]. - The company experienced a net cash flow from operating activities of ¥40,435,604.36, a slight decrease of 2.60% compared to ¥41,516,111.84 in 2021[19]. - In 2022, the company achieved a revenue of CNY 585.23 million, representing a year-on-year growth of 16.55%[48]. - The net profit attributable to shareholders reached CNY 72.41 million, an increase of 25.35% compared to the previous year[48]. - The company secured new contracts worth CNY 1.04 billion, a year-on-year increase of 43.42%[48]. - The total contract amount at the end of the reporting period was CNY 1.505 billion, reflecting a growth of 39.90% year-on-year[48]. Investment and Growth Strategy - The company aims to enhance its core service capabilities and expand brand awareness through a robust training and management system[32]. - The company is positioned in the SMO sector, which is increasingly important in the pharmaceutical R&D industry, driven by rising global pharmaceutical market demand and regulatory support for innovation[28]. - The forecast for China's pharmaceutical R&D investment is expected to grow from $32.7 billion in 2022 to $52.9 billion by 2026, with a compound annual growth rate of approximately 12.8%[29]. - The proportion of outsourced pharmaceutical R&D investment in China is expected to increase from 42.6% in 2022 to 52.2% by 2026[30]. - The company aims to leverage its extensive experience in clinical trial project execution to improve the project execution systems of clinical research institutions[39]. - The company plans to implement a three-year strategic plan to optimize organizational structure and enhance management innovation in 2023[94]. - The company is focused on enhancing project management efficiency and improving clinical trial outsourcing services through ongoing research and development[65]. Corporate Governance and Compliance - The company emphasizes risk prevention and sustainable development, enhancing internal controls and management levels[111]. - The company has established a complete business system and independent operational capabilities, ensuring asset independence from the controlling shareholder[115]. - The company maintains independence from its controlling shareholder, with no instances of fund occupation or guarantees provided to related parties[112]. - The company has implemented strict information disclosure practices, ensuring timely and accurate communication with investors[114]. - The company has a structured governance framework with a board of directors, supervisory board, and various committees to ensure effective management[116]. - The company has not reported any significant discrepancies between its governance practices and regulatory requirements[114]. - The company has established measures to prevent the illegal transfer of funds or profits through related party transactions[184]. - The company will adhere to the disclosure obligations related to related party transactions as per relevant laws and regulations[184]. Employee and Social Responsibility - The company has a comprehensive training system for new employees, ensuring they undergo training and assessment before officially joining[147]. - The company emphasizes a competitive and fair compensation system to attract and retain talent, including a stock option plan[146]. - The company has created 295 new jobs, actively fulfilling its social responsibility in employment[172]. - The company provided training for over 1,600 disabled individuals, achieving a satisfaction rate of over 94% in the interactive sessions[173]. - The company prioritizes the protection of employee rights, providing various benefits and support for female employees[170]. - The company achieved a 100% labor contract signing rate during the reporting period, with no incidents of child or forced labor[170]. Future Outlook and Projections - The company provided guidance for the next fiscal year, projecting revenue growth of 20% to $600 million[128]. - The company plans to implement cost-cutting measures, aiming for a 5% reduction in operational expenses[128]. - The company is focused on maximizing the return on investment from fundraising projects to enhance long-term profitability and investor returns[192]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[128]. - The company reported a positive outlook for 2023, projecting a revenue growth of 20% to reach approximately 1.8 billion RMB[195]. Risk Management - The company faces risks from potential declines in market demand for pharmaceutical research services and external factors affecting client budgets[96]. - The competitive landscape in the SMO industry is intensifying, necessitating continuous improvement in service quality to maintain profitability[97]. - Long project contract execution cycles pose risks of revenue deviation due to potential delays or early terminations[99]. - The company is implementing internal controls to manage costs and maintain gross margin levels amid increasing competition[99]. - The company is at risk of increased labor costs due to business expansion and rising living standards, which could negatively impact financial performance if operational efficiency does not improve concurrently[104]. Shareholder Engagement and Commitments - The company has established a complete shareholder meeting system, ensuring shareholders' rights to information and participation in decision-making[111]. - The company reported a 99.99% investor participation rate in the 2021 annual general meeting held on March 31, 2022[118]. - The company has committed to comply with laws and regulations regarding shareholder holdings and share changes during the holding period[176]. - The company guarantees to strictly fulfill all public commitments made during the issuance and listing process[189]. - The company will publicly disclose any failure to fulfill commitments in designated media and explain remedial actions taken[189].